The effect of levothyroxine on ECT Induced Memory Impairment in bipolar patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015071012018N3

Enrollment

Registered

2016-09-16

Start date

2016-08-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

BIPOLAR affective disorder. Bipolar affective disorder

Interventions

Intervention 1: tablet levothyroxine 0.1 mg daily fasting during ECT treatment. Intervention 2: Tablet Placebo(similar Levothyroxine) daily Fasting during ECT treatment.

Treatment - Drugs

tablet levothyroxine 0.1 mg daily fasting during ECT treatment

Tablet Placebo(similar Levothyroxine) daily Fasting during ECT treatment

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria:Diagnosis of bipolar disorder based on SCID questionnaire that its persian validity and reliability is confirmed??Presence of ECT indication is under recommendation of psychiatrist?Age between 18-64?consent letter of patient's parents.Exclusion criteria:Any contraindication of levothyroxine?Comorbidity of substance or alcohol dependence?Any organic brain disorder or mental retardation (based on history, physical exam and patient's records) or any cognitive impairment(MMSE<23) at begining of study?ECT less than 6 session?ECT induced delirium?not using at least one of standard mood stabilizers (sodium valproate ,lithium carbonate or carbamazepin)?use more than one of standard mood stabilizers (sodium valproate ,lithium carbonate or carbamazepin)?use more than one convulsion in ECT in at least half of sessions?siezure duration below 15 second in more than half of sessions?siezure duration higher thant 3 minutes in even one session?

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Memory impairment. Timepoint: Baseline and Then two weeks after completion of therapy ???. Method of measurement: wecsler memory tese.	—

Secondary

Measure	Time frame
Cognitin state. Timepoint: Baseline and Then two weeks after completion of therapy ???. Method of measurement: mmse.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Seyed Majid Hoseiny Hoshyar

Qazvin University of Medical Science

majidhooshyar@yahoo.com+98 28 3336 9923

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026